Medibact GuidesShop at Medibact

Stacking Module

SLU-PP-332 Stacking Module

SLU-PP-332 is a synthetic pan-ERR agonist marketed as an exercise mimetic, and it is not a peptide at all — a small molecule grouped here by market convention. That matters for stacking: its handling, route and evidence base do not follow peptide norms.

SLU-PP-332 Guide at MedibactSLU-PP-332 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking SLU-PP-332

  • SLU-PP-332 is a small-molecule ERR agonist, not a peptide. Reasoning transferred from peptide stacks about routes and handling does not automatically apply.
  • Its mechanism — oestrogen-related receptor agonism affecting mitochondrial biogenesis — is distinct from AMPK activation, so pairing with MOTS-c is not redundant.
  • Human data are essentially absent; the evidence is preclinical. Marketing describing it as an exercise replacement runs well ahead of that.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Mitochondrial / Metabolic Stack

SLU-PP-332 + MOTS-c + SS-31
Why it is proposed
Three different approaches to mitochondrial function — ERR agonism, AMPK signaling, and cardiolipin targeting. On mechanism this is genuinely non-overlapping.
What is reported in practice
Reported concurrently as separate compounds.
Cautions specific to this combination
Three compounds with thin-to-absent human data and no combination evidence. Mechanistic diversity does not compensate for that.

Body Recomposition Stack

SLU-PP-332 + 5-Amino-1MQ
Why it is proposed
Two metabolic small molecules acting through different targets — ERR agonism and NNMT inhibition.
What is reported in practice
Both are reported orally more than by injection.
Cautions specific to this combination
5-Amino-1MQ's human evidence is absent and unverifiable figures circulate for it. This pairing is two under-evidenced compounds rather than one.

GLP-1 Fat-Loss Support

SLU-PP-332 + Tirzepatide or Retatrutide
Why it is proposed
Metabolic small molecule alongside incretin therapy — unrelated mechanisms.
What is reported in practice
Separate administration on separate schedules.
Cautions specific to this combination
The incretin compounds are prescription medicines with documented interactions; adding an uncharacterised metabolic agent to one is a clinical question.

Endurance & Recovery

SLU-PP-332 + BPC-157 + TB-500
Why it is proposed
Metabolic/mitochondrial support alongside the repair pairing.
What is reported in practice
Separate compounds and schedules.
Cautions specific to this combination
No combination data; SLU-PP-332's route differs from the injected repair compounds.

What to avoid, and why

  • Treating it as a peptide for handling and route purposes — it is a small molecule.
  • Reading 'exercise mimetic' marketing as established; the evidence is preclinical.
  • Stacking it with 5-Amino-1MQ and treating the pair as well-characterised; neither is.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.